Novartis takes HuCAL-derived bimagrumab into Phase III
This article was originally published in Scrip
Novartis has begun a pivotal Phase II/III trial in sporadic inclusion body myositis (sIBM) patients with the HuCAL-derived antibody bimagrumab (BYM338). The event triggered an undisclosed milestone payment to MorphoSys, whose HuCAL library was used to identify the antibody. Financial details were not disclosed.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.